Prismic’s line of Nephrology products is based on palmitoylethanolamide, an endogenous fatty acid amide. Prismic acquired the worldwide rights to palmitoylethanolamide and the extensive portfolio of issued and pending U.S. and international patents from Epitech SpA.
Palmitoylethanolamide is a molecule supported by substantial clinical and safety data. Palmitoylethanolamide is of particular interest because of recent data indicating that this molecule displays anti-inflammatory, anti-fibrotic, and analgesic properties that would allow it to serve as a renal-sparing anti-inflammatory (one that does not damage the kidney). There are also early data that suggest that palmitoylethanolamide may reduce proteinuria.
Prismic has two lead products derived from palmitoylethanolamide in development for Chronic Kidney Disease (CKD).
NEFROGESIC™ is a patent protected, ultra-micronized formulation of palmitoylethanolamide in development to address inflammation and pain associated with CKD.
NEFROSIL™ is a uniquely formulated product in development, combining ultra-micronized palmitoylethanolamide with silymarin to demonstrate improvements in the albumin-creatinine ratios and reduction in proteinuria, and other markers associated with disease progression.
Recent data indicates that palmitoylethanolamide may have both a solo mechanism of action and a “potentiating” or “synergistic” effect when combined with narcotics and certain other drugs used for the treatment of severe chronic pain. Prismic plans to undertake proof-of-concept clinical studies to demonstrate the “potentiating” effect of our formulations of palmitoylethanolamide when administered concomitantly with drugs such as morphine, oxycodone, hydrocodone, and pregabalin. This means that Prismic’s palmitoylethanolamide formulations may enhance the effectiveness of these drugs, allowing for lower doses of the drugs to be used while achieving the desired therapeutic effect. This also means that there would be a consequent lessening or avoidance of adverse events/side effects and, in the case of opiates/narcotics, potentially, a delay in the onset of tolerance development.
Central Nervous System (CNS) Disorders
The company’s CNS line of products is based on extensive research that has been done that demonstrates the benefits of Omega-3 fatty acids, and in particular Eicosapentaenoic Acid (EPA) for people who suffer from Depression or Bipolar Disorder (depressive phase).
NEUREPA® is Prismic’s lead CNS product, a unique patented formulation of an Omega-3 triglyceride concentrate that is 92% EPA (Eicosapentaenoic Acid), has undergone both in-depth market research among Psychiatrists and Obstetricians/Gynecologists (OB/GYNs), and a field test among Psychiatrists, showing positive data and acceptance by physicians and patients. NEUREPA® was formulated and developed specifically to address the Omega-3 deficiency in patients suffering from Depression and Bipolar Disorder (Depressive phase).
Line extensions of NEUREPA® are being formulated for other related patient populations and conditions, and to provide extended patent life based on the company’s existing IP portfolio.
© Copyright by Prismic Pharmaceuticals, Inc.®, 2011-2017. All rights reserved. NEUREPA® by Prismic Pharmaceuticals, Inc®.
Prismic Pharmaceuticals, Inc.
Attn: Zachary Dutton
474 Grove Street, Suite 740
Worcester, Massachusetts 01605